Identification
NameMycophenolic acid
Accession NumberDB01024  (APRD01603, EXPT02208)
TypeSmall Molecule
GroupsApproved
Description

Mycophenolic acid is an an immunosuppresant drug and potent anti-proliferative, and can be used in place of the older anti-proliferative azathioprine. It is usually used as part of triple therapy including a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. It is also useful in research for the selection of animal cells that express the E. coli gene coding for XGPRT (xanthine guanine phosphoribosyltransferase).

Structure
Thumb
Synonyms
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
Micofenolico acido
Mycophenolate
Mycophenolsäure
External IDs 68618 / NSC-129185
Product Ingredients
IngredientUNIICASInChI KeyDetails
Mycophenolate sodiumWX877SQI1G 37415-62-6DOZYTHNHLLSNIK-JOKMOOFLSA-MDetails
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MyforticTablet, delayed release180 mg/1OralNovartis2004-02-27Not applicableUs
MyforticTablet, delayed release180 mgOralNovartis2005-02-11Not applicableCanada
MyforticTablet, delayed release360 mg/1OralNovartis2004-02-27Not applicableUs00078 0386 66 nlmimage10 a116d0a6
MyforticTablet, delayed release360 mgOralNovartis2005-02-11Not applicableCanada
MyforticTablet, delayed release180 mg/1OralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Sandoz Mycophenolic AcidTablet, delayed release360 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Mycophenolic AcidTablet, delayed release180 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-mycophenolic AcidTablet, delayed release180 mgOralApotex Corporation2014-07-02Not applicableCanada
Apo-mycophenolic AcidTablet, delayed release360 mgOralApotex Corporation2014-07-02Not applicableCanada
Mycophenolic AcidTablet, delayed release180 mg/1OralAmerincan Health Packaging2015-01-15Not applicableUs
Mycophenolic AcidTablet, delayed release360 mg/1OralGolden State Medical Supply2014-10-13Not applicableUs60505 2966 07 nlmimage10 923ec936
Mycophenolic AcidTablet, delayed release360 mg/1OralMylan Pharmaceuticals2014-01-08Not applicableUs
Mycophenolic AcidTablet, delayed release180 mg/1OralApotex Corporation2012-08-21Not applicableUs
Mycophenolic AcidTablet, delayed release360 mg/1OralAmerincan Health Packaging2015-01-15Not applicableUs
Mycophenolic AcidTablet, delayed release180 mg/1OralMylan Institutional2014-01-20Not applicableUs
Mycophenolic AcidTablet, delayed release360 mg/1OralApotex Corporation2014-08-19Not applicableUs
Mycophenolic AcidTablet, delayed release180 mg/1OralGolden State Medical Supply2014-10-13Not applicableUs
Mycophenolic AcidTablet, delayed release180 mg/1OralMylan Pharmaceuticals2014-01-08Not applicableUs
Mycophenolic AcidTablet, delayed release360 mg/1OralMylan Institutional2014-01-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MelbexNot Available
Brand mixturesNot Available
Categories
UNIIHU9DX48N0T
CAS number24280-93-1
WeightAverage: 320.3371
Monoisotopic: 320.125988372
Chemical FormulaC17H20O6
InChI KeyHPNSFSBZBAHARI-RUDMXATFSA-N
InChI
InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
IUPAC Name
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
SMILES
COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C
Pharmacology
Indication

For the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids.

Structured Indications
Pharmacodynamics

Mycophenolic acid is an antibiotic substance derived from Penicillium stoloniferum. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites.

Mechanism of action

Mycophenolic acid is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines, whereas other cell types can utilize salvage pathways, mycophenolic acid has potent cytostatic effects on lymphocytes. Mycophenolic acid inhibits proliferative responses of T- and B-lymphocytes to both mitogenic and allospecific stimulation. Addition of guanosine or deoxyguanosine reverses the cytostatic effects of mycophenolic acid on lymphocytes. Mycophenolic acid also suppresses antibody formation by B-lymphocytes. Mycophenolic acid prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection.

TargetKindPharmacological actionActionsOrganismUniProt ID
Inosine-5'-monophosphate dehydrogenase 1Proteinyes
inhibitor
HumanP20839 details
Inosine-5'-monophosphate dehydrogenase 2Proteinyes
inhibitor
HumanP12268 details
Related Articles
Absorption

Bioavailability following oral administration of Myfortic delayed-release tablet ranges from 70-95%

Volume of distribution
  • 54 ± 25 L
Protein binding

>98%

Metabolism

Mycophenolic acid is metabolized mainly by glucuronyl transferase to glucuronidated metabolites, predominantly the phenolic glucuronide, mycophenolic acid glucuronide (MPAG). MPAG does not manifest pharmacological activity. The acyl glucuronide minor metabolite has pharmacological activity similar to mycophenolic acid. The AUC ratio of Mycophenolic acid:MPAG:acyl glucuronide is approximately 1:24:0.28 at steady state.

SubstrateEnzymesProduct
Mycophenolic acid
Mycophenolic acid-acyl glucuronideDetails
Mycophenolic acid
6-O-desmethyl-mycophenolic acidDetails
Mycophenolic acid
Mycophenolic acid-7-O-glucuornideDetails
Route of eliminationNot Available
Half life

The mean elimination half-life for mycophenolic acid ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.

Clearance
  • 140 +/- 30 mL/min [Stable renal transplant patients]
Toxicity

Oral (LD50): Acute: 352 mg/kg [Rat], 1000 mg/kg [Mouse], and >6000 mg/kg [Rabbit]. Possible signs and symptoms of acute overdose could include the following: hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting, and dyspepsia.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 5-androstenedione.Experimental, Illicit
AbciximabMycophenolic acid may increase the anticoagulant activities of Abciximab.Approved
AcebutololMycophenolic acid may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Aceclofenac.Approved
AcenocoumarolMycophenolic acid may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Mycophenolic acid.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Mycophenolic acid.Approved, Vet Approved
AclarubicinMycophenolic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Mycophenolic acid.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alendronic acid.Approved
AliskirenMycophenolic acid may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololMycophenolic acid may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Amcinonide.Approved
AmdinocillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Amdinocillin resulting in a loss in efficacy.Withdrawn
AmikacinMycophenolic acid may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideMycophenolic acid may decrease the antihypertensive activities of Amiloride.Approved
AmoxicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Amoxicillin resulting in a loss in efficacy.Approved, Vet Approved
AmpicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Ampicillin resulting in a loss in efficacy.Approved, Vet Approved
AmrubicinMycophenolic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodMycophenolic acid may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with HMPL-004.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 4-Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Antipyrine.Approved
Antithrombin III humanMycophenolic acid may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanMycophenolic acid may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Acetovanillone.Investigational
ApramycinMycophenolic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Apremilast.Approved, Investigational
ArbekacinMycophenolic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinMycophenolic acid may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanMycophenolic acid may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololMycophenolic acid may decrease the antihypertensive activities of Arotinolol.Approved
AtenololMycophenolic acid may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Mycophenolic acid.Approved
AzidocillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Azidocillin resulting in a loss in efficacy.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mycophenolic acid.Approved
AzlocillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Azlocillin resulting in a loss in efficacy.Approved
BacampicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Bacampicillin resulting in a loss in efficacy.Approved
BalsalazideMycophenolic acid may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Mycophenolic acid.Investigational
BecaplerminMycophenolic acid may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMycophenolic acid may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mycophenolic acid.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mycophenolic acid.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Benoxaprofen.Withdrawn
Benzathine benzylpenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Benzathine benzylpenicillin resulting in a loss in efficacy.Approved, Vet Approved
BenzylpenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Benzylpenicillin resulting in a loss in efficacy.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Benzylpenicilloyl Polylysine resulting in a loss in efficacy.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mycophenolic acid.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Betamethasone.Approved, Vet Approved
BetaxololMycophenolic acid may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Betulinic Acid.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Mycophenolic acid.Approved, Investigational
BevantololMycophenolic acid may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololMycophenolic acid may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMycophenolic acid may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololMycophenolic acid may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Mycophenolic acid.Approved
BucillamineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bucillamine.Investigational
BucindololMycophenolic acid may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Budesonide.Approved
BufuralolMycophenolic acid may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideMycophenolic acid may decrease the diuretic activities of Bumetanide.Approved
BupranololMycophenolic acid may decrease the antihypertensive activities of Bupranolol.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mycophenolic acid.Approved
Calcium CarbonateCalcium carbonate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Mycophenolic acid.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mycophenolic acid.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Mycophenolic acid.Approved
CarbenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Carbenicillin resulting in a loss in efficacy.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mycophenolic acid.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Mycophenolic acid.Approved, Vet Approved, Withdrawn
CarteololMycophenolic acid may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolMycophenolic acid may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Celecoxib.Approved, Investigational
CeliprololMycophenolic acid may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinMycophenolic acid may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mycophenolic acid.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolic acid.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Mycophenolic acid.Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mycophenolic acid.Approved
CholestyramineThe serum concentration of Mycophenolic acid can be decreased when it is combined with Cholestyramine.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Trisalicylate-choline.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mycophenolic acid.Approved
CinoxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Ciprofloxacin.Approved, Investigational
Citric AcidMycophenolic acid may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clonixin.Approved
CloxacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Cloxacillin resulting in a loss in efficacy.Approved, Vet Approved
ColesevelamThe serum concentration of Mycophenolic acid can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Mycophenolic acid can be decreased when it is combined with Colestipol.Approved
Conjugated estrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Mycophenolic acid.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Curcumin.Investigational
CyclacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Cyclacillin resulting in a loss in efficacy.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Mycophenolic acid.Approved, Investigational
CyclosporineThe serum concentration of Mycophenolic acid can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateMycophenolic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinMycophenolic acid may increase the anticoagulant activities of Dalteparin.Approved
DarexabanMycophenolic acid may increase the anticoagulant activities of Ym150.Investigational
DaunorubicinMycophenolic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Deferasirox.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Mycophenolic acid.Approved
DesirudinMycophenolic acid may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Mycophenolic acid.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desmopressin.Approved
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Mycophenolic acid.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desoximetasone.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Mycophenolic acid.Approved
DexlansoprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with TAK-390MR.Approved
DextranMycophenolic acid may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Mycophenolic acid may increase the anticoagulant activities of Dextran 40.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mycophenolic acid.Approved, Vet Approved
DicloxacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Dicloxacillin resulting in a loss in efficacy.Approved, Vet Approved
DicoumarolMycophenolic acid may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Mycophenolic acid.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Mycophenolic acid.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Mycophenolic acid.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Mycophenolic acid.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Mycophenolic acid.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mycophenolic acid.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Mycophenolic acid.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Mycophenolic acid.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Mycophenolic acid.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mycophenolic acid.Approved, Investigational
DoxorubicinMycophenolic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Mycophenolic acid.Approved
DroxicamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ebselen.Investigational
Edetic AcidMycophenolic acid may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMycophenolic acid may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Mycophenolic acid.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mycophenolic acid.Approved
EnoxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Enoxacin.Approved
EnoxaparinMycophenolic acid may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Epirizole.Approved
EpirubicinMycophenolic acid may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneMycophenolic acid may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mycophenolic acid.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mycophenolic acid.Approved
EquileninThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Equilin.Approved
EsmololMycophenolic acid may decrease the antihypertensive activities of Esmolol.Approved
EsomeprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Mycophenolic acid.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Mycophenolic acid.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Mycophenolic acid.Approved
EstroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Estrone.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Mycophenolic acid.Approved
Etacrynic acidMycophenolic acid may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Mycophenolic acid.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Mycophenolic acid.Approved
Ethyl biscoumacetateMycophenolic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Mycophenolic acid.Approved
Etidronic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etofenamate.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Mycophenolic acid.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etoricoxib.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mycophenolic acid.Approved
FingolimodMycophenolic acid may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Mycophenolic acid.Approved, Withdrawn
FlucloxacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Flucloxacillin resulting in a loss in efficacy.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fludrocortisone.Approved
FluindioneMycophenolic acid may increase the anticoagulant activities of Fluindione.Investigational
FlumequineThe serum concentration of Mycophenolic acid can be decreased when it is combined with Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluprednidene.Approved, Withdrawn
FlurandrenolideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mycophenolic acid.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mycophenolic acid.Approved, Nutraceutical, Vet Approved
FondaparinuxMycophenolic acid may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumMycophenolic acid may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Mycophenolic acid.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mycophenolic acid.Approved
FramycetinMycophenolic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideMycophenolic acid may decrease the diuretic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with G17DT.Investigational
GabexateMycophenolic acid may increase the anticoagulant activities of Gabexate.Investigational
GanciclovirThe serum concentration of Ganciclovir can be increased when it is combined with Mycophenolic acid.Approved, Investigational
GatifloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Mycophenolic acid.Approved, Withdrawn
GemifloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Gemifloxacin.Approved, Investigational
GeneticinMycophenolic acid may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinMycophenolic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMycophenolic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Mycophenolic acid.Approved
GrepafloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with HE3286.Investigational
HeparinMycophenolic acid may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Mycophenolic acid.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Higenamine.Investigational
HydralazineMycophenolic acid may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mycophenolic acid.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mycophenolic acid.Approved
IbandronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Icatibant.Approved
IdarubicinMycophenolic acid may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Mycophenolic acid.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mycophenolic acid.Approved
IndenololMycophenolic acid may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mycophenolic acid.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Indoprofen.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with INGN 225.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mycophenolic acid.Approved, Investigational
IsavuconazoniumThe serum concentration of Mycophenolic acid can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Isoxicam.Withdrawn
KanamycinMycophenolic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Mycophenolic acid.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mycophenolic acid.Approved
LabetalolMycophenolic acid may decrease the antihypertensive activities of Labetalol.Approved
LandiololMycophenolic acid may decrease the antihypertensive activities of Aop200704.Investigational
LansoprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Lansoprazole.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Leflunomide.Approved, Investigational
LepirudinMycophenolic acid may increase the anticoagulant activities of Lepirudin.Approved
LevobunololMycophenolic acid may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Levofloxacin.Approved, Investigational
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Mycophenolic acid.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Mycophenolic acid.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Mycophenolic acid.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Mycophenolic acid.Approved
LomefloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Mycophenolic acid.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lumiracoxib.Approved, Investigational
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Mycophenolic acid.Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium HydroxideThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium oxide.Approved
Magnesium salicylateThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mycophenolic acid.Approved
ME-609The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mycophenolic acid.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Mycophenolic acid.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Mycophenolic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Mycophenolic acid.Approved, Vet Approved
MesalazineMycophenolic acid may increase the nephrotoxic activities of Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Mycophenolic acid.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Metamizole.Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Mycophenolic acid.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mycophenolic acid.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolic acid.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Methylprednisolone.Approved, Vet Approved
MeticillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Meticillin resulting in a loss in efficacy.Approved
MetipranololMycophenolic acid may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolic acid.Approved
MetoprololMycophenolic acid may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideMycophenolic acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MetronidazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Metronidazole.Approved
MezlocillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Mezlocillin resulting in a loss in efficacy.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mycophenolic acid.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Mycophenolic acid.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mycophenolic acid.Approved
MoxifloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mycophenolic acid.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nabumetone.Approved
NadololMycophenolic acid may decrease the antihypertensive activities of Nadolol.Approved
NadroparinMycophenolic acid may increase the anticoagulant activities of Nadroparin.Approved
NafamostatMycophenolic acid may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NafcillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Nafcillin resulting in a loss in efficacy.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Mycophenolic acid.Approved
Nalidixic AcidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Mycophenolic acid.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with NCX 1022.Investigational
NeamineMycophenolic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NeomycinMycophenolic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nepafenac.Approved
NetilmicinMycophenolic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nitroaspirin.Investigational
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Mycophenolic acid.Approved
NorfloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Norfloxacin.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Mycophenolic acid.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Mycophenolic acid.Approved
OfloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Ofloxacin.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Mycophenolic acid.Experimental
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mycophenolic acid.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mycophenolic acid.Approved
OlsalazineMycophenolic acid may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Mycophenolic acid.Investigational
OmeprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Mycophenolic acid.Approved
OxacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Oxacillin resulting in a loss in efficacy.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Mycophenolic acid.Approved
OxprenololMycophenolic acid may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mycophenolic acid.Approved, Vet Approved
PamidronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pamidronate.Approved
PantoprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Parecoxib.Approved
ParomomycinMycophenolic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Pazufloxacin.Investigational
PefloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Pefloxacin.Approved
PenbutololMycophenolic acid may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateMycophenolic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Mycophenolic acid.Approved
PhenindioneMycophenolic acid may increase the anticoagulant activities of Phenindione.Approved
PhenoxymethylpenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Phenoxymethylpenicillin resulting in a loss in efficacy.Approved, Vet Approved
PhenprocoumonMycophenolic acid may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Mycophenolic acid.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mycophenolic acid.Approved, Investigational
PindololMycophenolic acid may decrease the antihypertensive activities of Pindolol.Approved
PiperacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Piperacillin resulting in a loss in efficacy.Approved
PirarubicinMycophenolic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideMycophenolic acid may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mycophenolic acid.Approved, Investigational
PivampicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Pivampicillin resulting in a loss in efficacy.Approved
PivmecillinamThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Pivmecillinam resulting in a loss in efficacy.Approved
PlicamycinMycophenolic acid may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mycophenolic acid.Approved
PractololMycophenolic acid may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Mycophenolic acid.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with dehydroepiandrosterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Mycophenolic acid can be increased when it is combined with Probenecid.Approved
Procaine benzylpenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Procaine benzylpenicillin resulting in a loss in efficacy.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Propacetamol.Approved
PropranololMycophenolic acid may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Mycophenolic acid.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Mycophenolic acid.Experimental
Protein S humanMycophenolic acid may increase the anticoagulant activities of Protein S human.Approved
PrulifloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with PTC299.Investigational
PuromycinMycophenolic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Mycophenolic acid.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mycophenolic acid.Approved
RabeprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mycophenolic acid.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mycophenolic acid.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Resveratrol.Experimental, Investigational
ReviparinMycophenolic acid may increase the anticoagulant activities of Reviparin.Approved
RibostamycinMycophenolic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifabutinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rimexolone.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with CDX-110.Investigational
RisedronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Risedronate.Approved, Investigational
RivaroxabanMycophenolic acid may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rofecoxib.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Mycophenolic acid.Approved
RosoxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Mycophenolic acid.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Mycophenolic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mycophenolic acid.Experimental
SeratrodastThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Seratrodast.Approved
SevelamerThe serum concentration of Mycophenolic acid can be decreased when it is combined with Sevelamer.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mycophenolic acid.Approved
SisomicinMycophenolic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolMycophenolic acid may decrease the antihypertensive activities of Sotalol.Approved
SP1049CMycophenolic acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Sparfloxacin.Approved
SpectinomycinMycophenolic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Mycophenolic acid.Approved
SpironolactoneMycophenolic acid may decrease the antihypertensive activities of Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with SRT501.Investigational
StreptomycinMycophenolic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinMycophenolic acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulbactamThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Sulbactam resulting in a loss in efficacy.Approved
SulfasalazineMycophenolic acid may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Mycophenolic acid.Approved
SulodexideMycophenolic acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Mycophenolic acid.Investigational
SultamicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Sultamicillin resulting in a loss in efficacy.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Mycophenolic acid.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Mycophenolic acid.Approved
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Mycophenolic acid.Approved, Investigational
TacrolimusMycophenolic acid may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Mycophenolic acid.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Mycophenolic acid.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mycophenolic acid.Approved
TazobactamThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Tazobactam resulting in a loss in efficacy.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mycophenolic acid.Approved, Investigational
TemafloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Mycophenolic acid.Experimental, Investigational
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mycophenolic acid.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tiaprofenic acid.Approved
TicarcillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Ticarcillin resulting in a loss in efficacy.Approved, Vet Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tiludronate.Approved, Vet Approved
TimololMycophenolic acid may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tixocortol.Approved
TobramycinMycophenolic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TofacitinibMycophenolic acid may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mycophenolic acid.Approved
TorasemideMycophenolic acid may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mycophenolic acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Mycophenolic acid.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mycophenolic acid.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mycophenolic acid.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMycophenolic acid may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mycophenolic acid.Approved, Vet Approved
TrovafloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Mycophenolic acid.Approved
ValaciclovirThe serum concentration of Mycophenolic acid can be increased when it is combined with Valaciclovir.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Valdecoxib.Investigational, Withdrawn
ValganciclovirThe serum concentration of Valganciclovir can be increased when it is combined with Mycophenolic acid.Approved, Investigational
ValrubicinMycophenolic acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mycophenolic acid.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Mycophenolic acid.Approved
WarfarinMycophenolic acid may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMycophenolic acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Mycophenolic acid.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zomepirac.Withdrawn
ZorubicinMycophenolic acid may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Bernard J. Abbott, John G. Whitney, "Method of preparing mycophenolic acid glucoside." U.S. Patent US4234684, issued January, 1976.

US4234684
General References
  1. Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS: Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess. 2005 May;9(21):1-179, iii-iv. [PubMed:15899149 ]
External Links
ATC CodesL04AA06 — Mycophenolic acid
AHFS Codes
  • 92:00.00
PDB Entries
FDA labelNot Available
MSDSDownload (74 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0WithdrawnTreatmentMultiple Myeloma (MM) / Myeloma-Multiple1
1CompletedTreatmentDrug Interaction Potentiation1
1CompletedTreatmentEnd Stage Renal Disease (ESRD) / Transplantation, Kidney1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentPrimary Sjogren's Syndrome1
1RecruitingTreatmentAgnogenic Myeloid Metaplasia / Leukemias / Malignant Lymphomas / Smith-Magenis Syndrome1
1RecruitingTreatmentTransplantation, Liver1
1, 2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
1, 2CompletedTreatmentGraft Versus Host Disease (GVHD) / Malignancies, Hematologic1
1, 2CompletedTreatmentMalignancies, Hematologic1
1, 2CompletedTreatmentTransplantation, Kidney1
1, 2RecruitingBasic ScienceTransplantation, Kidney1
1, 2RecruitingTreatmentAdult Living Donor Kidney Transplant Recipients / Living Kidney Donors / Transplant, Kidney1
1, 2RecruitingTreatmentScleroderma, Systemic / Severe Systemic Sclerosis1
1, 2Unknown StatusTreatmentHematologic Diseases1
2Active Not RecruitingPreventionGraft Versus Host Disease (GVHD)1
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas1
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentNeoplasms, Malignant1
2CompletedTreatmentNephritis, Lupus1
2CompletedTreatmentTransplantation, Renal1
2RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Juvenile Myelomonocytic Leukemia / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Cytopenia With Multilineage Dysplasia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
2RecruitingTreatmentAcute myeloid leukaemia (in remission) / Acute Myeloid Leukaemias (AML) / Aplastic Anaemia (AA) / Chronic Myelomonocytic Leukemia / Indolent Non-Hodgkin's Lymphomas / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Neoplasms, Malignant / Plasma Cell Myeloma / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ring Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts1
2RecruitingTreatmentAllogeneic peripheral haematopoietic stem cell transplant / Neuroepithelial Tumor / Tumors, Solid1
2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2SuspendedTreatmentCrohn's Disease (CD)1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / All / AML / Chronic Lymphocytic Leukaemia (CLL) / CLL / Leukemias / Lymphoma, Hodgkins / Malignancies, Hematologic / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL) / Plasma Cell Myeloma1
2TerminatedTreatmentLeukemias / Myelodysplastic Syndromes1
2TerminatedTreatmentMalignant Lymphomas1
2Unknown StatusTreatmentChronic Renal Insufficiency / Transplantation, Liver1
2WithdrawnTreatmentDiabetes, Diabetes Mellitus Type 11
2, 3RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
3Active Not RecruitingTreatmentUveitis, Intermediate1
3CompletedPreventionTransplantation, Kidney1
3CompletedTreatmentAutoimmune Diseases1
3CompletedTreatmentGlomerulonephritis minimal lesion1
3CompletedTreatmentKidney Diseases1
3CompletedTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentPancreas Transplantation / Transplantation, Kidney1
3CompletedTreatmentRejection, Transplant / Transplantation, Kidney1
3CompletedTreatmentRenal Interstitial Fibrosis1
3CompletedTreatmentTransplant, Kidney4
3CompletedTreatmentTransplant; Failure, Kidney1
3CompletedTreatmentTransplantation, Kidney2
3CompletedTreatmentTransplantation, Liver3
3CompletedTreatmentTransplantation, Renal3
3Enrolling by InvitationNot AvailableDiabetes, Diabetes Mellitus Type 1 / Islet Transplantation1
3RecruitingTreatmentChronic Kidney Disease (CKD)1
3TerminatedNot AvailableSarcoidosis, Pulmonary1
3TerminatedTreatmentGraft Versus Host Disease (GVHD)1
3TerminatedTreatmentNephritis, Lupus1
3TerminatedTreatmentSystemic Lupus Erythematosus (SLE)1
3Unknown StatusTreatmentHeart Transplant Patients1
4Active Not RecruitingPreventionInfections, Cytomegalovirus / Transplantation Infection1
4Active Not RecruitingTreatmentChronic Kidney Disease (CKD) / End Stage Renal Disease (ESRD) / Hemodialysis-dependent patients / Renal Replacement Therapies / Transplantation, Renal1
4Active Not RecruitingTreatmentCytomegalovirus / Transplantation, Kidney1
4Active Not RecruitingTreatmentTransplantation, Renal1
4CompletedNot AvailableEnd Stage Liver Diseases1
4CompletedPreventionAdverse Effects / Transplantation, Kidney1
4CompletedPreventionChronic Hepatitis C Infection1
4CompletedPreventionTransplantation, Kidney1
4CompletedSupportive CareTransplantation, Renal1
4CompletedTreatmentBK Virus Infection1
4CompletedTreatmentBioavailability / Concomitant Medication After Renal Transplantation / Drug Interactions / Immunosuppressive Medication After Renal Transplantation1
4CompletedTreatmentChronic Renal Failure (CRF)1
4CompletedTreatmentDisorder Related to Renal Transplantation / Infections, Cytomegalovirus1
4CompletedTreatmentEnd Stage Renal Disease (ESRD)1
4CompletedTreatmentEnd-Stage Renal Disease (ESRD)1
4CompletedTreatmentGastrointestinal Lesions / Signs and Symptoms, Digestive1
4CompletedTreatmentGastrointestinal Problems / Transplantation, Renal1
4CompletedTreatmentGastrointestinal Symptoms / Heart Transplantation1
4CompletedTreatmentInfections, Cytomegalovirus / Renal Transplant Failure / Transplant; Complication, Rejection1
4CompletedTreatmentKidney Transplant Recipients1
4CompletedTreatmentLiver Cirrhosis / Liver Transplant Disorder1
4CompletedTreatmentRenal Function1
4CompletedTreatmentRenal Transplanted Recipients1
4CompletedTreatmentTransplant, Kidney2
4CompletedTreatmentTransplant, Kidney / Transplantation, Kidney1
4CompletedTreatmentTransplantation, Kidney2
4CompletedTreatmentTransplantation, Liver1
4CompletedTreatmentTransplantation, Renal3
4Not Yet RecruitingTreatmentGastrointestinal Disorder, Functional / Kidney Transplant Rejection1
4Not Yet RecruitingTreatmentImmunosuppression After Renal Transplantation / Transplant, Kidney1
4RecruitingPreventionInfections, Cytomegalovirus1
4RecruitingTreatmentAntibody Mediated Rejection / End Stage Renal Disease (ESRD)1
4RecruitingTreatmentChronic Renal Failure (CRF) / Graft Failure / Kidney Transplant Rejection / Transplant; Failure, Kidney1
4RecruitingTreatmentGlomerulonephritis minimal lesion1
4RecruitingTreatmentHepatocellular,Carcinoma1
4RecruitingTreatmentImmunosuppression1
4RecruitingTreatmentImplant or Graft; Rejection1
4RecruitingTreatmentInfections, Cytomegalovirus / Transplantation Infection1
4RecruitingTreatmentKidney Transplant Rejection / Other Complications of Kidney Transplant1
4TerminatedPreventionSkin Cancers / Transplantation, Kidney1
4TerminatedPreventionTransplantation, Kidney1
4TerminatedPreventionTransplantation, Renal1
4TerminatedTreatmentTransplantation, Kidney1
4TerminatedTreatmentTransplantation, Renal2
4Unknown StatusNot AvailableTransplantation, Lung1
4Unknown StatusPreventionDiabetes / Rejection, Transplant1
4Unknown StatusPreventionKidney; Complications, Allograft1
4Unknown StatusTreatmentInfections, Cytomegalovirus1
4Unknown StatusTreatmentTransplant, Kidney1
4Unknown StatusTreatmentTransplantation, Organ1
4Unknown StatusTreatmentTransplantation, Renal1
4WithdrawnTreatmentCardiovascular Disease (CVD) / Cardiovascular Outcomes / Kidney Transplant Recipients / Transplantation, Kidney1
4WithdrawnTreatmentLiving Donor Kidney Transplants Patients1
4WithdrawnTreatmentReperfusion Injury / Transplantation, Kidney / Transplantation, Renal1
4WithdrawnTreatmentTransplantation, Liver1
Not AvailableCompletedNot AvailableGI Disturbance1
Not AvailableCompletedTreatmentArthritis / Systemic Lupus Erythematosus (SLE)1
Not AvailableCompletedTreatmentHigh Model for End-Stage Liver Disease (MELD) Score1
Not AvailableCompletedTreatmentImmunosuppression2
Not AvailableNo Longer AvailableNot AvailableDiabetes, Diabetes Mellitus Type 11
Not AvailableNot Yet RecruitingNot AvailableAcute Rejection of Renal Transplant / Biopsy Proven Acute Rejection (BPAR) / Bone Diseases / Cardiovascular Risk Factors / Graft Failure / HLA Antibody Production / Infection NOS / Mortality / Non-HLA Antibody Production / Post Transplant Diabetes Mellitus / Quality of Life1
Not AvailableRecruitingNot AvailableNephritis, Lupus1
Not AvailableRecruitingPreventionDiabetes, Diabetes Mellitus Type 11
Not AvailableRecruitingPreventionImmunosuppression / Renal Failure1
Not AvailableRecruitingTreatmentDisorder Related to Renal Transplantation / Effects of Immunosuppressant Therapy1
Not AvailableTerminatedTreatmentAcute Rejection / Transplantation, Renal1
Not AvailableTerminatedTreatmentTransplantation, Kidney1
Not AvailableTerminatedTreatmentTransplantation, Liver1
Not AvailableUnknown StatusNot AvailableUveitis1
Not AvailableUnknown StatusTreatmentMyasthenia Gravis1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet, delayed releaseOral180 mg
Tablet, delayed releaseOral360 mg
Tablet, delayed releaseOral180 mg/1
Tablet, delayed releaseOral360 mg/1
Prices
Unit descriptionCostUnit
Myfortic 360 mg Enteric Coated Tabs8.0USD tab
Myfortic 360 mg tablet7.69USD tablet
Myfortic 180 mg tablet3.85USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2250906 No2006-10-032017-04-10Canada
US6025391 No1997-04-102017-04-10Us
US6172107 No1997-04-102017-04-10Us
US6306900 No1998-02-272018-02-27Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)141 °CPhysProp
water solubilityInsolubleNot Available
logP2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0355 mg/mLALOGPS
logP2.36ALOGPS
logP3.53ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.57ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.06 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity85.23 m3·mol-1ChemAxon
Polarizability32.95 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9409
Blood Brain Barrier+0.5826
Caco-2 permeable-0.5583
P-glycoprotein substrateSubstrate0.8058
P-glycoprotein inhibitor INon-inhibitor0.7888
P-glycoprotein inhibitor IIInhibitor0.545
Renal organic cation transporterNon-inhibitor0.8199
CYP450 2C9 substrateNon-substrate0.8305
CYP450 2D6 substrateNon-substrate0.8575
CYP450 3A4 substrateSubstrate0.6934
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7237
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.9619
BiodegradationReady biodegradable0.5888
Rat acute toxicity2.9907 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.753
hERG inhibition (predictor II)Non-inhibitor0.6329
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-002r-0490000000-99420edc8894323b59c3View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-014i-0009000000-b99d88ff2ddeb6977c4aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-014i-0149000000-ed6b854b4f9af495c8d8View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0006-0972000000-12d0e80f109d1fa6eb11View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0006-0950000000-2e6c3543fe3f9f4e0790View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0006-0930000000-e7a74fbe76e7141ec5f3View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-022c-0910000000-27f7c0023a8b7e5b4d66View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-014i-0009000000-4aba5ee4ba77899b36fbView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-014i-0149000000-497b49ab395f3319c943View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0006-0971000000-68634f04b665bb0e68a3View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0006-0950000000-37f2ee0320d2ec560b93View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0f6x-0930000000-500359a3fd82c686ff99View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-006x-0900000000-6d04c3395aae26f88529View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-002r-0590000000-fe2f27357ba775714c5aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-014i-0009000000-8f75c9bc48b5eb019974View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-014i-0009000000-57a06531623d00c32d13View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-002r-0490000000-700501110e03f998e99bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-002r-0490000000-d857a6e047fc52e09e65View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-0udi-0009000000-8855932a0a5c9af1f1f6View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phthalides. These are compounds containing a 3-hydrocarbylidene-2-benzofuran-1(3H)-one moiety,.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsocoumarans
Sub ClassIsobenzofuranones
Direct ParentPhthalides
Alternative ParentsAnisoles / Medium-chain fatty acids / Alkyl aryl ethers / Methyl-branched fatty acids / Hydroxy fatty acids / Heterocyclic fatty acids / Unsaturated fatty acids / Dicarboxylic acids and derivatives / Vinylogous acids / Lactones
SubstituentsPhthalide / Anisole / Medium-chain fatty acid / Alkyl aryl ether / Branched fatty acid / Methyl-branched fatty acid / Heterocyclic fatty acid / Hydroxy fatty acid / Dicarboxylic acid or derivatives / Fatty acyl
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors2-benzofurans, monocarboxylic acid, phenols, gamma-lactone (CHEBI:168396 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Rna binding
Specific Function:
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in t...
Gene Name:
IMPDH1
Uniprot ID:
P20839
Uniprot Name:
Inosine-5'-monophosphate dehydrogenase 1
Molecular Weight:
55405.365 Da
References
  1. Dzidic A, Prgomet C, Mohr A, Meyer K, Bauer J, Meyer HH, Pfaffl MW: Effects of mycophenolic acid on inosine monophosphate dehydrogenase I and II mRNA expression in white blood cells and various tissues in sheep. J Vet Med A Physiol Pathol Clin Med. 2006 May;53(4):163-9. [PubMed:16629948 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Rna binding
Specific Function:
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in t...
Gene Name:
IMPDH2
Uniprot ID:
P12268
Uniprot Name:
Inosine-5'-monophosphate dehydrogenase 2
Molecular Weight:
55804.495 Da
References
  1. Vannozzi F, Filipponi F, Di Paolo A, Danesi R, Urbani L, Bocci G, Catalano G, De Simone P, Mosca F, Del Tacca M: An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. Transplant Proc. 2004 Nov;36(9):2787-90. [PubMed:15621150 ]
  2. Wang J, Zeevi A, Webber S, Girnita DM, Addonizio L, Selby R, Hutchinson IV, Burckart GJ: A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics. 2007 Apr;17(4):283-90. [PubMed:17496727 ]
  3. Penuelas S, Noe V, Morales R, Ciudad CJ: Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH. Med Sci Monit. 2005 Jan;11(1):BR6-12. [PubMed:15614187 ]
  4. Yam P, Jensen M, Akkina R, Anderson J, Villacres MC, Wu J, Zaia JA, Yee JK: Ex vivo selection and expansion of cells based on expression of a mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells. Mol Ther. 2006 Aug;14(2):236-44. Epub 2006 May 2. [PubMed:16647299 ]
  5. Dzidic A, Prgomet C, Mohr A, Meyer K, Bauer J, Meyer HH, Pfaffl MW: Effects of mycophenolic acid on inosine monophosphate dehydrogenase I and II mRNA expression in white blood cells and various tissues in sheep. J Vet Med A Physiol Pathol Clin Med. 2006 May;53(4):163-9. [PubMed:16629948 ]
  6. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Uniprot Name:
UDP-glucuronosyltransferase 1-1
Molecular Weight:
59590.91 Da
References
  1. Dostalek M, Court MH, Hazarika S, Akhlaghi F: Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55. doi: 10.1124/dmd.110.036608. Epub 2010 Dec 1. [PubMed:21123165 ]
  2. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Uniprot Name:
UDP-glucuronosyltransferase 1-9
Molecular Weight:
59940.495 Da
References
  1. Dostalek M, Court MH, Hazarika S, Akhlaghi F: Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55. doi: 10.1124/dmd.110.036608. Epub 2010 Dec 1. [PubMed:21123165 ]
  2. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6. [PubMed:15470161 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Uniprot Name:
UDP-glucuronosyltransferase 2B7
Molecular Weight:
60694.12 Da
References
  1. Dostalek M, Court MH, Hazarika S, Akhlaghi F: Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55. doi: 10.1124/dmd.110.036608. Epub 2010 Dec 1. [PubMed:21123165 ]
  2. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6. [PubMed:15470161 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A7
Uniprot ID:
Q9HAW7
Uniprot Name:
UDP-glucuronosyltransferase 1-7
Molecular Weight:
59818.315 Da
References
  1. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 3 lacks transferase activity but acts as a negative regulator of isoform 1 (By similarity).
Gene Name:
UGT1A6
Uniprot ID:
P19224
Uniprot Name:
UDP-glucuronosyltransferase 1-6
Molecular Weight:
60750.215 Da
References
  1. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]
Drug created on June 13, 2005 07:24 / Updated on August 08, 2017 11:07